Compare Crispr Therapeutics AG (CRSP) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Twilio Inc — how do they compare? Crispr Therapeutics AG trades at $53.82 (market cap $5.23B), while Twilio Inc trades at $246.36 (market cap $39.31B). The key difference: Twilio Inc is far larger — about 7.5× Crispr Therapeutics AG's market cap, and Twilio Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | TWLO | |
|---|---|---|
Market Cap | $5.23B | $39.31B |
Sector | Health | Technology |
52-Week High | $76.78 | $255.95 |
52-Week Low | $44.34 | $95.23 |
Enterprise Value | $3.65B | $37.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Twilio (TWLO) trades at $250.06, up 3.64% with strong technical momentum and bullish moving average signals. The stock has delivered three consecutive earnings beats, with Q2 2026 EPS of $1.47 beating expectations by 11%. Revenue growth accelerated to 22% year-over-year in Q2, prompting management to raise full-year guidance to 18-18.5% growth. The company achieved record free cash flow generation with margins improving significantly.
Twilio presents compelling growth prospects with accelerating revenue and robust cash flow generation. However, elevated valuation multiples (P/E 35.35, EV/EBITDA 75.54) and overbought technical indicators suggest near-term consolidation risk. Analyst consensus remains strongly bullish with 77% buy ratings and $266.31 price target, representing 6.5% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
